- Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy2019 | First Faculty of Medicine
- Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy2021 | First Faculty of Medicine
- Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression2011 | First Faculty of Medicine
- Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update2020 | Publication without faculty affiliation
- The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and associated with defective CD46 expression2021 | First Faculty of Medicine
- Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy2023 | First Faculty of Medicine
- Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy2020 | First Faculty of Medicine
- Budesonid potvrdil efekt v léčbě IgA nefropatie ve studii NefIgArd: konec éry systémových kortikosteroidů?2023 | First Faculty of Medicine
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial2017 | First Faculty of Medicine
- Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study2016 | First Faculty of Medicine
- Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)2013 | Second Faculty of Medicine
- Expanding options of supportive care in IgA nephropathy2023 | First Faculty of Medicine
- New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies2022 | First Faculty of Medicine
- IgA nephropathy: the lectin pathway and implications for targeted therapy2023 | First Faculty of Medicine
- The Influence of Vascular Endothelial Growth Factor (VEGF) Polymorphism on the Progression of Chronic Glomerulonephritides2011 | First Faculty of Medicine
- A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence2023 | Faculty of Physical Education and Sport
- Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors2022 | Second Faculty of Medicine
- Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis2022 | First Faculty of Medicine
- Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort2017 | Publication without faculty affiliation
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial2023 | First Faculty of Medicine